David A. Siegel Evelo Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.46 - $3.55 $122,640 - $298,200	-84,000 Reduced 76.16%	26,300 $55,000
Q1 2022 May 16, 2022	SELL	$2.66 - $6.63 $532 - $1,326	-200 Reduced 0.18%	110,300 $374,000
Q4 2021 Feb 14, 2022	SELL	$6.07 - $12.0 $182,707 - $361,200	-30,100 Reduced 21.41%	110,500 $671,000
Q3 2021 Nov 15, 2021	BUY	$6.79 - $13.9 $136,479 - $279,390	20,100 Added 16.68%	140,600 $990,000
Q2 2021 Aug 16, 2021	BUY	$9.43 - $16.6 $512,049 - $901,380	54,300 Added 82.02%	120,500 $1.66 Million
Q1 2021 May 17, 2021	BUY	$9.71 - $18.6 $642,802 - $1.23 Million	66,200 New	66,200 $708,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.